At a glance
ClinicalIndex Comparison RecordN/ACompleted· 14 enrolled
Drug / intervention
Raltegravirdrug
Likely dose
Raltegravir 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Raltegravir Substitution for Enfuvirtide in Patients Suffering From Injection Site Reactions (ISRs): The Raleve Pilot Study
In Brief
A clinical study evaluating Raltegravir for HIV Infections. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to: * Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide, * Monitor the safety and efficacy of raltegravir, and * Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartOct 2007
Primary CompletionMar 2009
Study CompletionDec 2010
TodayJul 2026
First PostedAug 31, 2007
Enrollment StartOct 1, 2007
Primary CompletionMar 1, 2009
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.8 years ago
Interventions
Raltegravirdrug
400 mg Twice daily for 24 weeks